BioCentury | Jan 10, 2020
Emerging Company Profile

NorthSea: Engineering fatty acids for NASH

With its structurally engineered fatty acid platform and a candidate that can hit the three primary mechanisms behind NASH, NorthSea thinks it can succeed in the hepatic and cardiometabolic disease space where so many others...
BC Week In Review | Dec 15, 2017
Financial News

Dutch NASH play NorthSea debuts with €25M

On Dec. 12, former Dezima Pharma B.V. investors and executives have reconnected to launch non-alcoholic steatohepatitis company NorthSea Therapeutics B.V. (Naarden, the Netherlands). The newco raised €25 million ($29.5 million) in a series A round...
BC Extra | Dec 12, 2017
Financial News

Dutch NASH play NorthSea debuts with €25M

Former Dezima Pharma B.V. investors and executives have reconnected to launch non-alcoholic steatohepatitis company NorthSea Therapeutics B.V. (Naarden, the Netherlands). The newco raised €25 million ($29.5 million) in a series A round led by Forbion...
BC Week In Review | Sep 16, 2013
Company News

Teva, BASF, Par Pharmaceutical endocrine/metabolic news

The U.S. Court of Appeals for the Federal Circuit reversed in part a lower court's 2012 ruling upholding U.S. Patent Nos. 5,656,667 and 5,502,077 covering Pronova Biopharma ASA 's lipid-lowering drug, Lovaza . Chemicals company BASF...
BC Week In Review | May 13, 2013
Clinical News

N-3 polyunsaturated fatty acids: Phase III data

Researchers at the institute reported data from a double-blind, Italian Phase III trial in 12,513 patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction (MI) showing that...
BC Week In Review | Jan 21, 2013
Company News

Pronova, Takeda sales and marketing update

Takeda launched Lotriga in Japan to treat hyperlipidemia. Takeda has exclusive, Japanese development and marketing rights to the omega-3-acid ethyl esters from Pronova under a 2005 deal. Takeda said the National Health Insurance price for...
BioCentury | Dec 17, 2012
Finance

Herkulean return

Herkulean return Herkules Capital, the largest shareholder of Pronova Biopharma ASA (OSE:PRON), is looking at a more than 13x return when chemicals company BASF AG (Xetra:BAS; LSE:BFA) acquires the biotech this week. Herkules first invested...
BC Week In Review | Dec 3, 2012
Company News

Pronova, BASF deal

Chemicals company BASF will acquire Pronova for NOK12.50 per share in cash, or about NOK3.8 billion ($662.5 million). The price is a 4% premium to Pronova's close of NOK12 on Nov. 20, before the deal...
BioCentury | Dec 3, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Actelion Ltd. (SIX:ATLN) was up CHF0.96 to CHF45.90 last week after EMA accepted for review an MAA for Opsumit macitentan to treat pulmonary arterial hypertension (PAH). The company submitted an NDA to FDA...
BC Extra | Nov 27, 2012
Company News

BASF to acquire Pronova

Chemicals company BASF AG (Xetra:BAS; LSE:BFA) will acquire Pronova Biopharma ASA (OSE:PRON) for NOK12.50 per share in cash, or about NOK3.8 billion ($651.6 million). The price is a 4% premium to Pronova's close of NOK12...
Items per page:
1 - 10 of 56
BioCentury | Jan 10, 2020
Emerging Company Profile

NorthSea: Engineering fatty acids for NASH

With its structurally engineered fatty acid platform and a candidate that can hit the three primary mechanisms behind NASH, NorthSea thinks it can succeed in the hepatic and cardiometabolic disease space where so many others...
BC Week In Review | Dec 15, 2017
Financial News

Dutch NASH play NorthSea debuts with €25M

On Dec. 12, former Dezima Pharma B.V. investors and executives have reconnected to launch non-alcoholic steatohepatitis company NorthSea Therapeutics B.V. (Naarden, the Netherlands). The newco raised €25 million ($29.5 million) in a series A round...
BC Extra | Dec 12, 2017
Financial News

Dutch NASH play NorthSea debuts with €25M

Former Dezima Pharma B.V. investors and executives have reconnected to launch non-alcoholic steatohepatitis company NorthSea Therapeutics B.V. (Naarden, the Netherlands). The newco raised €25 million ($29.5 million) in a series A round led by Forbion...
BC Week In Review | Sep 16, 2013
Company News

Teva, BASF, Par Pharmaceutical endocrine/metabolic news

The U.S. Court of Appeals for the Federal Circuit reversed in part a lower court's 2012 ruling upholding U.S. Patent Nos. 5,656,667 and 5,502,077 covering Pronova Biopharma ASA 's lipid-lowering drug, Lovaza . Chemicals company BASF...
BC Week In Review | May 13, 2013
Clinical News

N-3 polyunsaturated fatty acids: Phase III data

Researchers at the institute reported data from a double-blind, Italian Phase III trial in 12,513 patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction (MI) showing that...
BC Week In Review | Jan 21, 2013
Company News

Pronova, Takeda sales and marketing update

Takeda launched Lotriga in Japan to treat hyperlipidemia. Takeda has exclusive, Japanese development and marketing rights to the omega-3-acid ethyl esters from Pronova under a 2005 deal. Takeda said the National Health Insurance price for...
BioCentury | Dec 17, 2012
Finance

Herkulean return

Herkulean return Herkules Capital, the largest shareholder of Pronova Biopharma ASA (OSE:PRON), is looking at a more than 13x return when chemicals company BASF AG (Xetra:BAS; LSE:BFA) acquires the biotech this week. Herkules first invested...
BC Week In Review | Dec 3, 2012
Company News

Pronova, BASF deal

Chemicals company BASF will acquire Pronova for NOK12.50 per share in cash, or about NOK3.8 billion ($662.5 million). The price is a 4% premium to Pronova's close of NOK12 on Nov. 20, before the deal...
BioCentury | Dec 3, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Actelion Ltd. (SIX:ATLN) was up CHF0.96 to CHF45.90 last week after EMA accepted for review an MAA for Opsumit macitentan to treat pulmonary arterial hypertension (PAH). The company submitted an NDA to FDA...
BC Extra | Nov 27, 2012
Company News

BASF to acquire Pronova

Chemicals company BASF AG (Xetra:BAS; LSE:BFA) will acquire Pronova Biopharma ASA (OSE:PRON) for NOK12.50 per share in cash, or about NOK3.8 billion ($651.6 million). The price is a 4% premium to Pronova's close of NOK12...
Items per page:
1 - 10 of 56